Plasmon-Controlled Fluorescence and Cardiac Markers

描述（由申请人提供）：我们建议开发等离子体控制荧光（PCF）的使用，并将该技术应用于心脏标志物的检测。PCF传感的有效使用将取决于对荧光团与金属纳米结构的相互作用的理解。这些研究将为在医学诊断和生物技术中使用等离子体控制荧光（PCF）提供基础。这一建议是从我们对随机大小的金属颗粒（银岛膜，SIF）和平面表面对附近荧光团的影响的研究中得出的。这些研究表明，荧光团-金属相互作用导致通过增强局部入射场和将激发态能量耦合到等离子体激元中来修改激发和发射，然后辐射到远场用于检测。我们的具体目标是：具体目标1：金属纳米结构的纳米织物，包括规则的纳米颗粒阵列、纳米孔阵列和同心纳米环。具体目标2。确定这些结构对附近荧光团的影响，包括强度、寿命、光稳定性和发射方向性。我们还将确定距离表面对这些光谱特性的影响。具体目标3。将这些结构的近场特性与它们对荧光的影响相关联。结构的近场特性将使用NSOM通过实验确定，NSOM将用于测量和成像从金属表面传播的倏逝场和光。这些结果将与相同结构的时域有限差分（FDTD）计算进行比较。具体目标4。使用金属纳米结构测定心肌标志物肌红蛋白、肌酸酐激酶（CK-MB）、心肌肌钙蛋白I（cTnI）和B型利钠肽（BNB）。对于这些分析物，我们将进行特异性、灵敏度和重现性检测。肌红蛋白的临床相关浓度相对较高，该标志物将用于初始试验开发。心肌肌钙蛋白I和BMP以较低的浓度存在，它们的检测将推动用于高灵敏度检测的纳米结构的发展。

DESCRIPTION (provided by applicant): We propose to develop the use of plasmon-controlled fluorescence (PCF) and to apply this technology to the detection of cardiac markers. The effective use of PCF for sensing will depend on an understanding of the interactions of fluorophores with metallic nanostructures. These studies will provide the basis for using plasmon-controlled fluorescence (PCF) in medical diagnostics and biotechnology. This proposal evolved from our studies of the effects of random size metallic particles (silver island films, SIFs) and planar surfaces on nearby fluorophores. These studies showed that fluorophore-metal interactions result in modification of excitation and emission by enhancement of local incident fields and coupling of excited state energy into plasmons, which then radiate to the far field for detection. Our Specific Aims are: Specific Aim 1: Nanofabrication of metallic nanostructures, including regular nanoparticle arrays, nanohole arrays and concentric nanorings. Specific Aim 2. Determine the effects of these structures on nearby fluorophores, including intensities, lifetimes, photostability and directionality of the emission. We will also determine the effect of distance from the surface on these spectral properties. Specific Aim 3. Correlate the near-field properties of these structures with their effects on fluorescence. Near-field properties of the structures will be determined experimentally using NSOM, which will be used to measure and image the evanescent field and light propagating away from the metal surfaces. These results will be compared with finite-difference time-domain (FDTD) calculations for the same structure. Specific Aim 4. Use the metallic nanostructures for assays of the cardiac markers myoglobin, creatinine kinase (CK-MB), cardiac troponin l(cTnl) and B-type natriuretic peptide (BNB). For these analytes we will perform testing for specificity, sensitivity and reproducibility. The clinically relevant concentration of myogloblin are relatively high and this marker will be used for initial assay development. Cardiac troponin I and BMP are present at lower concentrations and their detection will drive development of nanostructures for high sensitivity detection.